Skip to main content

Illumina, Inc.

corporate_fare Company Profile

Illumina, Inc.

ILMN·NASDAQ·Industrial Applications And Services·CIK 0001110803

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis. The company offers instruments and consumables, including reagents, flow cells, and library preparation products. Its product portfolio includes whole-genome sequencing kits, designed to sequence entire genomes of varying sizes and complexities, and targeted resequencing kits, which sequence exomes, specific genes, RNA, or other genomic regions of interest. Illumina also provides services such as whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. The company serves a diverse customer base, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina markets and distributes its products directly to customers and through life-science distributors across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company collaborates with Labcorp Holdings Inc. to develop oncology treatments using sequencing solutions and has a data partnership with the Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare diseases. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Illumina, Inc. (NASDAQ:ILMN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for ILMN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Illumina Appoints Renowned Genomics Leader as CMO; CCO Departs for CEO Role

Financial Snapshot

Fiscal year ended December 28, 2025
Revenue
$4.34B
Net Income
$850M
Diluted EPS
$5.45
Op. Cash Flow
$1.08B
Free Cash Flow
$931M
Gross Profit
$2.87B
Operating Income
$807M
Cash & Equivalents
$1.42B
Debt / Equity
0.00×
Net Margin
19.6%
Shares Outstanding
153M sh
Source: 10-K · filed 2026-02-12 · accession 0001110803-26-000024
$207.18 +0.73% today
52-week range · as of 2026-09-04 $88 – $231.81
Market cap
$31.17B
Volume
2.4M (1.2× avg)
3-mo avg 2M
Live data · 2026-09-14 03:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ILMN - Filings & News (Page 2)

ILMN
Jan 08, 2026, 4:39 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $145.94
Real-time Price: $207.18 info
Change: +$61.24 (+42%) info
Market Cap: $31.174B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets